125 related articles for article (PubMed ID: 22298359)
1. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
Bymaster FP; Golembiowska K; Kowalska M; Choi YK; Tarazi FI
Synapse; 2012 Jun; 66(6):522-32. PubMed ID: 22298359
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
Bymaster FP; Katner JS; Nelson DL; Hemrick-Luecke SK; Threlkeld PG; Heiligenstein JH; Morin SM; Gehlert DR; Perry KW
Neuropsychopharmacology; 2002 Nov; 27(5):699-711. PubMed ID: 12431845
[TBL] [Abstract][Full Text] [Related]
3. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder.
Viggiano D; Ruocco LA; Arcieri S; Sadile AG
Neural Plast; 2004; 11(1-2):133-49. PubMed ID: 15303310
[TBL] [Abstract][Full Text] [Related]
4. Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis?
Glaser PE; Surgener SP; Grondin R; Gash CR; Palmer M; Castellanos FX; Gerhardt GA
J Neurosci Methods; 2006 Feb; 151(1):62-7. PubMed ID: 16451810
[TBL] [Abstract][Full Text] [Related]
5. Behavioural effects of monoamine reuptake inhibitors on symptomatic domains in an animal model of attention-deficit/hyperactivity disorder.
Hiraide S; Ueno K; Yamaguchi T; Matsumoto M; Yanagawa Y; Yoshioka M; Togashi H
Pharmacol Biochem Behav; 2013 Apr; 105():89-97. PubMed ID: 23380523
[TBL] [Abstract][Full Text] [Related]
6. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
[TBL] [Abstract][Full Text] [Related]
7. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
Golembiowska K; Kowalska M; Bymaster FP
Synapse; 2012 May; 66(5):435-44. PubMed ID: 22213370
[TBL] [Abstract][Full Text] [Related]
8. A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.
Schmeichel BE; Zemlan FP; Berridge CW
Neuropharmacology; 2013 Jan; 64(1):321-8. PubMed ID: 22796428
[TBL] [Abstract][Full Text] [Related]
9. Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro.
Yoon SY; dela Peña I; Kim SM; Woo TS; Shin CY; Son KH; Park H; Lee YS; Ryu JH; Jin M; Kim KM; Cheong JH
Arch Pharm Res; 2013 Jan; 36(1):134-40. PubMed ID: 23371806
[TBL] [Abstract][Full Text] [Related]
10. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice.
Koda K; Ago Y; Cong Y; Kita Y; Takuma K; Matsuda T
J Neurochem; 2010 Jul; 114(1):259-70. PubMed ID: 20403082
[TBL] [Abstract][Full Text] [Related]
11. Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats.
Umehara M; Ago Y; Fujita K; Hiramatsu N; Takuma K; Matsuda T
Eur J Pharmacol; 2013 Feb; 702(1-3):250-7. PubMed ID: 23376565
[TBL] [Abstract][Full Text] [Related]
12. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
Dhir A; Kulkarni SK
Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558
[TBL] [Abstract][Full Text] [Related]
13. The neuropsychopharmacology of attention-deficit/hyperactivity disorder.
Pliszka SR
Biol Psychiatry; 2005 Jun; 57(11):1385-90. PubMed ID: 15950012
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).
Liang Y; Shaw AM; Boules M; Briody S; Robinson J; Oliveros A; Blazar E; Williams K; Zhang Y; Carlier PR; Richelson E
J Pharmacol Exp Ther; 2008 Nov; 327(2):573-83. PubMed ID: 18689611
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
Roessner V; Sagvolden T; Dasbanerjee T; Middleton FA; Faraone SV; Walaas SI; Becker A; Rothenberger A; Bock N
Neuroscience; 2010 Jun; 167(4):1183-91. PubMed ID: 20211696
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
17. Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
Ruocco LA; Carnevale UA; Treno C; Sadile AG; Melisi D; Arra C; Ibba M; Schirru C; Carboni E
Behav Brain Res; 2010 Jun; 210(1):99-106. PubMed ID: 20156489
[TBL] [Abstract][Full Text] [Related]
18. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.
Berridge CW; Devilbiss DM; Andrzejewski ME; Arnsten AF; Kelley AE; Schmeichel B; Hamilton C; Spencer RC
Biol Psychiatry; 2006 Nov; 60(10):1111-20. PubMed ID: 16806100
[TBL] [Abstract][Full Text] [Related]
19. Early stress and chronic methylphenidate cross-sensitize dopaminergic responses in the adolescent medial prefrontal cortex and nucleus accumbens.
Jezierski G; Zehle S; Bock J; Braun K; Gruss M
J Neurochem; 2007 Dec; 103(6):2234-44. PubMed ID: 17924950
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo.
Tolliver BK; Newman AH; Katz JL; Ho LB; Fox LM; Hsu K; Berger SP
J Pharmacol Exp Ther; 1999 Apr; 289(1):110-22. PubMed ID: 10086994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
